Last reviewed · How we verify
NSAID (Ketorolac/Ibuprofen)
NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Acute pain (ketorolac), Mild to moderate pain and inflammation (ibuprofen), Fever reduction.
At a glance
| Generic name | NSAID (Ketorolac/Ibuprofen) |
|---|---|
| Sponsor | Thomas Jefferson University |
| Drug class | Non-steroidal anti-inflammatory drug (NSAID) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Inflammation |
| Phase | FDA-approved |
Mechanism of action
Ketorolac and ibuprofen are non-selective COX inhibitors that block both COX-1 and COX-2 enzymes. By reducing prostaglandin production, they suppress inflammatory mediators and provide analgesic and antipyretic effects. Ketorolac is a potent short-acting NSAID typically used for acute moderate-to-severe pain, while ibuprofen is a milder, longer-acting NSAID used for mild-to-moderate pain and inflammation.
Approved indications
- Acute moderate-to-severe pain (ketorolac)
- Mild-to-moderate pain and inflammation (ibuprofen)
- Fever reduction
- Rheumatoid arthritis and osteoarthritis
Common side effects
- Gastrointestinal ulceration and bleeding
- Dyspepsia
- Nausea
- Renal impairment
- Cardiovascular events (myocardial infarction, stroke)
- Headache
- Dizziness
Key clinical trials
- Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid (PHASE2)
- Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial (PHASE2)
- Safety of Short-course of NSAIDs in Pediatric Patients With CKD (PHASE4)
- NSAID Use After Robotic Partial Nephrectomy (PHASE2)
- Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies (PHASE4)
- ICE-T Pain Regimen for Total Laparoscopic Hysterectomy (PHASE4)
- A Randomized Trial of NSAID Dosing Strategies (PHASE4)
- Novel Multimodal Pain Control Protocol for Minimally Invasive Gynecologic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NSAID (Ketorolac/Ibuprofen) CI brief — competitive landscape report
- NSAID (Ketorolac/Ibuprofen) updates RSS · CI watch RSS
- Thomas Jefferson University portfolio CI